F. Locatelli Et Al. , "Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial," BONE MARROW TRANSPLANTATION , vol.56, pp.74-76, 2021
Locatelli, F. Et Al. 2021. Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial. BONE MARROW TRANSPLANTATION , vol.56 , 74-76.
Locatelli, F., Polverelli, N., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., ... Musso, M.(2021). Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial. BONE MARROW TRANSPLANTATION , vol.56, 74-76.
Locatelli, Franco Et Al. "Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial," BONE MARROW TRANSPLANTATION , vol.56, 74-76, 2021
Locatelli, Franco Et Al. "Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial." BONE MARROW TRANSPLANTATION , vol.56, pp.74-76, 2021
Locatelli, F. Et Al. (2021) . "Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial." BONE MARROW TRANSPLANTATION , vol.56, pp.74-76.
@article{article, author={Franco Locatelli Et Al. }, title={Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial}, journal={BONE MARROW TRANSPLANTATION}, year=2021, pages={74-76} }